imatinib actavis group 100 mg
actavis group ptc ehf (1) - imatinib - tablett, filmdrasjert - 100 mg
imatinib actavis group 400 mg
actavis group ptc ehf (1) - imatinib - tablett, filmdrasjert - 400 mg
imatinib mylan 400 mg
mylan ab - imatinib - tablett, filmdrasjert - 400 mg
imatinib mylan 100 mg
mylan ab - imatinib - tablett, filmdrasjert - 100 mg
normosang 25 mg/ ml
recordati rare diseases - hemin, humant - konsentrat til infusjonsvæske, oppløsning - 25 mg/ ml
lorviqua
pfizer europe ma eeig - lorlatinib - karsinom, ikke-småcellet lunge - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
iclusig 15 mg
orifarm as - ponatinibhydroklorid - tablett, filmdrasjert - 15 mg
imatinib cipla 400 mg
cipla europe nv - imatinibmesilat - kapsel, hard - 400 mg
imatinib cipla 100 mg
cipla europe nv - imatinibmesilat - kapsel, hard - 100 mg
imatinib sandoz 400 mg
sandoz - københavn - imatinibmesilat - tablett, filmdrasjert - 400 mg